These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 34931674)

  • 21. [Oral nucleos(t)ide analogues antiviral therapy reduces HBV-related HCC: consensus and contention].
    Han C; Dou XG
    Zhonghua Gan Zang Bing Za Zhi; 2021 Apr; 29(4):293-296. PubMed ID: 33979951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy.
    Alshuwaykh O; Daugherty T; Cheung A; Goel A; Dhanasekaran R; Ghaziani TT; Ahmed A; Dronamraju D; Kumari R; Kwong A; Nguyen M; Kim WR; Kwo PY
    Hepatol Commun; 2022 Nov; 6(11):3052-3061. PubMed ID: 36004713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors associated with the biphasic kinetics of serum HBV RNA in patients with HBeAg-positive chronic hepatitis B treated with nucleos(t)ide analogues.
    Liu S; Liu Z; Li W; Zhou B; Liang X; Fan R; Deng R; Hou J; Sun J
    Aliment Pharmacol Ther; 2020 Aug; 52(4):692-700. PubMed ID: 32613672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis.
    Wang X; Liu X; Dang Z; Yu L; Jiang Y; Wang X; Yan Z
    Gut Liver; 2020 Mar; 14(2):232-247. PubMed ID: 31158948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
    Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Nucleos(t)ide Analogs on Patients with Intermediate and Advanced Hepatitis B Virus-Related Hepatocellular Carcinoma.
    Jian ZW; Wu XW; Chen ZX; Wang JC; Peng JY; Lao XM
    Dig Dis Sci; 2019 Aug; 64(8):2187-2198. PubMed ID: 30815819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
    Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
    Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients.
    Kim GA; Han S; Choi GH; Choi J; Lim YS
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1169-1179. PubMed ID: 32291781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy.
    Cheung KS; Seto WK; Wong DK; Lai CL; Yuen MF
    J Viral Hepat; 2017 Aug; 24(8):654-661. PubMed ID: 28185363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Liver histological status and clinic outcome in HBeAg-negative chronic hepatitis B with low viral load].
    Deng DL; Jiang JN; Su MH; Wang RM; Zang WW; Ling XZ; Wei HL; Liang XS; Zhou HK; He WM; Guo RS
    Zhonghua Gan Zang Bing Za Zhi; 2020 Dec; 28(12):1013-1017. PubMed ID: 34865348
    [No Abstract]   [Full Text] [Related]  

  • 31. Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up.
    Zhang W; Wang X; Wang Y; Zhao X; Duan W; Wang Q; Wu X; Kong Y; Ma H; You H; Ou X; Jia J
    Medicine (Baltimore); 2017 Nov; 96(44):e8454. PubMed ID: 29095292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma.
    Honda M; Shirasaki T; Terashima T; Kawaguchi K; Nakamura M; Oishi N; Wang X; Shimakami T; Okada H; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S
    J Infect Dis; 2016 Apr; 213(7):1096-106. PubMed ID: 26621908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score.
    Kaneko S; Kurosaki M; Joko K; Marusawa H; Kondo M; Kojima Y; Uchida Y; Kimura H; Tsuji K; Yagisawa H; Kusakabe A; Kobashi H; Akahane T; Tamaki N; Kirino S; Abe T; Yoshida H; Matsushita T; Hasebe C; Izumi N
    Sci Rep; 2020 Aug; 10(1):13021. PubMed ID: 32747646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease.
    Cho JY; Paik YH; Sohn W; Cho HC; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Gut; 2014 Dec; 63(12):1943-50. PubMed ID: 24615378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues.
    Hosaka T; Suzuki F; Kobayashi M; Fujiyama S; Kawamura Y; Sezaki H; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    Aliment Pharmacol Ther; 2019 Feb; 49(4):457-471. PubMed ID: 30663078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.
    Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Tanaka J
    J Gastroenterol Hepatol; 2017 Feb; 32(2):451-458. PubMed ID: 27288655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of antiviral therapy on post-hepatectomy outcome for hepatitis B-related hepatocellular carcinoma.
    Chong CC; Wong GL; Lai PB
    World J Gastroenterol; 2014 May; 20(20):6006-12. PubMed ID: 24876723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of interferon or nucleos(t)ide analogs on hepatitis B-related hepatocellular carcinoma].
    Liu ZH; Sun J
    Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):842-845. PubMed ID: 31941239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B.
    Kawaguchi K; Honda M; Ohta H; Terashima T; Shimakami T; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Komura T; Unoura M; Kaneko S
    J Gastroenterol; 2018 Jun; 53(6):740-751. PubMed ID: 28849280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The development of hepatocarcinoma after long-term antivirus treatment of Chinese patients with chronic hepatitis B virus infection: Incidence, long-term outcomes and predictive factors.
    Li ZQ; Hu CL; Yu P; Gu XY; Zhang JJ; Li H; Zhang HY; Lv J; Liu YM; Zeng QL; Yan JY; Yu ZJ; Zhang Y
    Clin Res Hepatol Gastroenterol; 2017 Jun; 41(3):311-318. PubMed ID: 28237828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.